Related Experiment Video

Updated: Jul 11, 2025

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.5K

Randomized phase III trial in extended stage small cell lung cancer comparing first line platinum in combination with

Morten Mau-Sørensen1, Jonas Gerner-Rasmussen1, Olfred Hansen2

  • 1Department of Oncology, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark.

Acta Oncologica (Stockholm, Sweden)
|November 7, 2023
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.3K
Author Spotlight: Establishing a Murine Non-Small Cell Lung Cancer Model for Developing Nanoformulations of Anticancer Drugs
05:11

Author Spotlight: Establishing a Murine Non-Small Cell Lung Cancer Model for Developing Nanoformulations of Anticancer Drugs

Published on: May 10, 2024

1.0K

Related Experiment Videos

Last Updated: Jul 11, 2025

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.5K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.3K
Author Spotlight: Establishing a Murine Non-Small Cell Lung Cancer Model for Developing Nanoformulations of Anticancer Drugs
05:11

Author Spotlight: Establishing a Murine Non-Small Cell Lung Cancer Model for Developing Nanoformulations of Anticancer Drugs

Published on: May 10, 2024

1.0K

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K

Articles linked to this work by shared authors, journal, and citation graph.

The prognostic potential of an immunology score in patients treated with curative surgery for non-small cell lung cancer.

Journal of cancer research and clinical oncology·2026

Circulating tumor DNA-guided response evaluation in patients with previously treated gastroesophageal adenocarcinoma.

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association·2026

Controversies in neuroendocrine neoplasms: An European Neuroendocrine Tumor Society position statement on the role of surgery of the primary tumour in metastatic small intestinal and pancreatic neuroendocrine tumours.

Journal of neuroendocrinology·2026

The prognostic value of methylated ctDNA, soluble PD-L1, and NK-cell activity on the risk of relapse after curative radiotherapy of non-small cell lung cancer.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2026

ctDNA guided immunotherapy in patients with advanced non-small cell lung cancer: a nationwide Danish, randomised, intervention study (PRELUCA-PRediction in LUng CAncer Treatment) - study protocol.

BMJ open·2026

Zolbetuximab as a gastric lineage-directed immunotherapy: mechanistic rationale and translational evidence in CLDN18.2-positive gastroesophageal adenocarcinoma.

Expert review of anticancer therapy·2026

Tools for providing information to patients about high-tech medical resources for treatment of cancer.

Acta oncologica (Stockholm, Sweden)·2026

Primary treatment and relative survival by stage and age in vaginal carcinoma: a population-based SweGCG study.

Acta oncologica (Stockholm, Sweden)·2026

Operationalizing fear of cancer recurrence care: a modified Delphi study establishing a consensus-based clinical pathway for Danish cancer survivors.

Acta oncologica (Stockholm, Sweden)·2026

FIN-EGFR: real-world treatment outcomes by EGFR mutational subtypes in NSCLC in Southern Finland.

Acta oncologica (Stockholm, Sweden)·2026

Disparities in initiating standard first-line cancer treatment and survival for patients with an immigrant background: a Danish register-based cohort study.

Acta oncologica (Stockholm, Sweden)·2026

Fatigue 5 years after treatment for rectal cancer – results from the QoLiRECT study

Acta oncologica (Stockholm, Sweden)·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us